fb-pixel
Mass. Movers

Vertex shares jump on cystic fibrosis trial

Vertex Pharmaceuticals’s waterfront headquarters
Vertex Pharmaceuticals’s waterfront headquarters(Globe staff/file 2013)

Shares of Vertex Pharmaceuticals Inc. skyrocketed following the release of a phase 3 clinical trial that showed a combination of two cystic fibrosis drugs it developed helped people with the deadly disease breathe more easily, raising hopes the treatment could be on the market by late next year. CEO Jeffrey Leiden said the encouraging study results mean the company is likely to file for approval of the treatment in the United States and Europe by the end of the year, and will seek priority review by regulators.